Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.67 |
| ▸ | KDR | P35968 | 4/20 | 0.65 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.65 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.65 |
| ▸ | FLT1 | P17948 | 1/20 | 0.65 |
| ▸ | RET | P07949 | 1/20 | 0.64 |
| ▸ | KIF5B | P33176 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100955 | 0.92 | KDR (0.75) | EGFRKDREPHA2EPHB4ERBB2 | |
| SCHEMBL28631617 | 0.88 | EGFR (0.66) | EGFRKDREPHA2EPHB4ERBB2 | |
| SCHEMBL29781309 | 0.88 | EGFR (0.73) | EGFRKDREPHA2EPHB4ERBB2 | |
| SCHEMBL29781300 | 0.88 | EGFR (0.66) | EGFRKDREPHA2EPHB4ERBB2 | |
| SCHEMBL202827 | 0.88 | EGFR (0.73) | EGFRKDREPHA2EPHB4ERBB2 | |
| SCHEMBL29988516 | 0.88 | EGFR (0.66) | EGFRKDREPHA2EPHB4ERBB2 | |
| SCHEMBL4448821 | 0.88 | EGFR (0.66) | EGFRKDREPHA2EPHB4ERBB2 | |
| SCHEMBL21541701 | 0.88 | EGFR (0.66) | EGFRKDREPHA2EPHB4ERBB2 | |
| Methane SCHEMBL5123634 | 0.87 | EGFR (0.72) | EGFRKDREPHA2EPHB4ERBB2 | |
| SCHEMBL16075706 | 0.87 | EGFR (0.67) | EGFRKDREPHA2EPHB4ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20180016259-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2018-01-18 | — | — | US | disclosed |
| US-9718806-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160340342-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | ASTRAZENECA AB (SE) | 2016-11-24 | — | — | US | disclosed |
| US-9375432-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2016-06-28 | — | — | US | disclosed |
| US-20150320751-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | ASTRAZENECA AB (SE) | 2015-11-12 | — | — | US | disclosed |
| US-9066979-B2 | Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | ASTRAZENECA AB (SE) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320751-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | EGFR, ABL1, ERBB2 | EGFR 1/4885KDR 78/4885EPHA2 561/4885 |
| US-20180016259-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | EGFR, ERBB2, ABL1 | EGFR 1/4885KDR 63/4885EPHA2 670/4885 |
| US-20160340342-A1 | QUINAZOLINE INHIBITORS OF ACTIVATING MUTANT FORMS OF EPIDERMAL GROWTH FACTOR RECEPTOR | EGFR, ABL1, ERBB2 | EGFR 1/4885KDR 78/4885EPHA2 561/4885 |
| US-20140255428-A1 | Quinazoline Inhibitors of activating mutant forms of Epidermal Growth Factor Receptor | EGFR, ERBB2, ABL1 | EGFR 1/4885KDR 74/4885EPHA2 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.